---
title: Mechanisms of Ultra-acute Hyperglycemia After Successful Resuscitation From Out-of-hospital Cardiac Arrest
nct_id: NCT01968148
overall_status: COMPLETED
sponsor: Helsinki University Central Hospital
study_type: OBSERVATIONAL
primary_condition: Heart Arrest
countries: Finland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01968148.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01968148"
ct_last_update_post_date: 2018-03-13
last_seen_at: "2026-05-12T06:44:29.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Mechanisms of Ultra-acute Hyperglycemia After Successful Resuscitation From Out-of-hospital Cardiac Arrest

**NCT ID:** [NCT01968148](https://clinicaltrials.gov/study/NCT01968148)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Helsinki University Central Hospital
- **Conditions:** Heart Arrest, Cardiac Arrest
- **Start Date:** 2013-11
- **Completion Date:** 2015-07-30
- **CT.gov Last Update:** 2018-03-13

## Brief Summary

The aim of the study is to describe the mechanisms of ultra-acute hyperglycemic response after return of spontaneous circulation (ROSC) in patients suffering out-of-hospital cardiac arrest. The investigators hypothesize that ischemia and reperfusion injury leads decreased secretion of insulin and glucose-like peptide 1 (GLP-1).

Two blood samples will be drawn: (1.) Immediately after ROSC and (2.) 60 minutes after first sample. Concentrations of glucose, insulin, glucagon and GLP-1 will be compared between the samples.

Metabolic profile will be compared between: (1.) diabetic and non-diabetic patients and (2.) survivors and non-survivors.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* age ≥18 years
* witnessed cardiac arrest
* interval form emergency call to return of spontaneous circulation 10-45 minutes

Exclusion Criteria:

* severe pre-arrest disability leading to withdrawing treatment in prehospital phase
* no concent from next of kin
```

## Primary Outcomes

- **Change in level of insulin** _(time frame: 60 minutes)_
- **Change in level of glucagon** _(time frame: 60 minutes)_

## Secondary Outcomes

- **Blood cortisol level** _(time frame: 60 minutes after ROSC)_
- **Blood interleukin-6 level** _(time frame: 60 minutes after ROSC)_
- **Change in blood glucose level** _(time frame: 60 minutes)_
- **Change in level of GLP-1** _(time frame: 60 minutes)_

## Locations (2)

- Helsinki Emergency Medical Services, Helsinki, Finland
- Helsinki Area Helicopter Emergency Medical Services, Vantaa, Finland

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.helsinki emergency medical services|helsinki||finland` — added _(2026-05-12)_
- `locations.helsinki area helicopter emergency medical services|vantaa||finland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01968148.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01968148*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*